Literature DB >> 30174935

Apatinib for EGFR-TKI and chemotherapy refractory in an advanced lung cancer patient: a case report.

Ying Chen1,2, Junping Gong3, Huiming Zhou1,2, Xiujuan Qu1,2, Yuee Teng1,2, Yunpeng Liu1,2, Bo Jin1,2.   

Abstract

Entities:  

Year:  2018        PMID： 30174935      PMCID： PMC6106002          DOI： 10.21037/jtd.2018.06.136

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  20 in total

1.  A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung.

Authors:  Natasha B Leighl; Luis E Raez; Benjamin Besse; Peter J Rosen; Fabrice Barlesi; E Massarelli; Nashat Gabrail; Lowell L Hart; Kathy S Albain; Lloyd Berkowitz; Ostap Melnyk; Frances A Shepherd; Lars Sternas; Judie Ackerman; Zhenming Shun; Vincent A Miller; Roy S Herbst
Journal:  J Thorac Oncol       Date:  2010-07       Impact factor: 15.609

2.  YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.

Authors:  Shu Tian; Haitian Quan; Chengying Xie; Haiyi Guo; Fangfang Lü; Yongping Xu; Jin Li; Liguang Lou
Journal:  Cancer Sci       Date:  2011-05-09       Impact factor: 6.716

3.  A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).

Authors:  Qing Zhou; Cai-cun Zhou; Gong-yan Chen; Ying Cheng; Cheng Huang; Li Zhang; Chong-rui Xu; Ai-wu Li; Hong-hong Yan; Jian Su; Xu-chao Zhang; Jin-ji Yang; Yi-long Wu
Journal:  Lung Cancer       Date:  2014-01-05       Impact factor: 5.705

4.  Simultaneous determination of apatinib and its four major metabolites in human plasma using liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study.

Authors:  Juefang Ding; Xiaoyan Chen; Xiaojian Dai; Dafang Zhong
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-03-26       Impact factor: 3.205

Review 5.  Response to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma with the Rare Epidermal Growth Factor Receptor Mutation S768I: a Retrospective Analysis and Literature Review.

Authors:  Xiaoli Zhu; Qianming Bai; Yongming Lu; Peng Qi; Jianhui Ding; Jialei Wang; Xiaoyan Zhou
Journal:  Target Oncol       Date:  2017-02       Impact factor: 4.493

Review 6.  Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales.

Authors:  Asmaa E El-Kenawi; Azza B El-Remessy
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

7.  Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.

Authors:  George R Blumenschein; Ulrich Gatzemeier; Frank Fossella; David J Stewart; Lisa Cupit; Frank Cihon; James O'Leary; Martin Reck
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

8.  National estimates of cancer prevalence in China, 2011.

Authors:  Rongshou Zheng; Hongmei Zeng; Siwei Zhang; Tianhui Chen; Wanqing Chen
Journal:  Cancer Lett       Date:  2015-10-13       Impact factor: 8.679

9.  Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.

Authors:  Eng-Huat Tan; Glenwood D Goss; Ravi Salgia; Benjamin Besse; David R Gandara; Nasser H Hanna; James Chih-Hsin Yang; Raymond Thertulien; Michael Wertheim; Julien Mazieres; Thomas Hensing; Christa Lee; Neeraj Gupta; Rajendra Pradhan; Jiang Qian; Qin Qin; Frank A Scappaticci; Justin L Ricker; Dawn M Carlson; Ross A Soo
Journal:  J Thorac Oncol       Date:  2011-08       Impact factor: 15.609

10.  Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway.

Authors:  Chen Lin; Shanshan Wang; Weiwei Xie; Rongliang Zheng; Yu Gan; Jianhua Chang
Journal:  Oncotarget       Date:  2016-09-13
View more
  1 in total

1.  A single-arm, prospective study of apatinib mesylate plus pemetrexed in patients of advanced non-squamous non-small cell lung cancer after failure of previous chemotherapy.

Authors:  Shuang Dong; Wuling Ou; Yi Zhong; Xianmin Zhu; Qian Cai; Jing Zhang; Fengming Ran; Yu Qian; Jun Wang; Sheng Hu
Journal:  Ann Transl Med       Date:  2022-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.